2-Oxo-1-Pyrrolidine Pharmaceutical Compositions for Immediate Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of 2-oxo-1-pyrrolidine derivatives, such as Brivaracetam and Seletracetam, face challenges in achieving immediate release formulations that meet in vitro dissolution requirements, particularly in maintaining high drug release within specified time frames as per regulatory guidelines.
Innovation Solution
A pharmaceutical composition comprising 2-oxo-1-pyrrolidine derivatives combined with cyclodextrin agents, along with other excipients like disintegrants and diluents, is formulated to ensure immediate release, utilizing a dry granulation process that enhances compaction and dissolution profiles, reducing sticking issues and requiring lower compression pressures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional pharmaceutical compositions are used, then the formulation is simple, but the in vitro dissolution requirement of 85% release in 15 minutes is not met
Solution Approach 1:
The patent employs a composite formulation containing 2-oxo-1-pyrrolidine derivatives combined with cyclodextrin agents and other excipients. This composite material approach enables the formulation to meet the stringent in vitro dissolution requirement of 85% release in 15 minutes while maintaining manufacturability through established dry granulation processes.
2Strength
If high compression pressure is applied during compaction, then the tablets are dense, but sticking issues occur and drug release is delayed
Solution Approach 1:
The patent introduces cyclodextrin agents as intermediary substances that facilitate the compaction process. These agents act as mediators between the active ingredient and the compression force, enabling tablet formation at reduced compression pressures while preventing sticking and maintaining immediate drug release properties.
Solution Approach 2:
The formulation optimizes multiple parameters including the type and amount of cyclodextrin agent (0.1% to 60% w/w), disintegrant content (1% to 20% w/w), and diluent characteristics to achieve optimal compactibility. This parameter optimization allows tablets to be formed at lower compression pressures without compromising structural integrity or drug release kinetics.
3Productivity
If the formulation meets immediate release criteria, then the dissolution is rapid, but the formulation complexity increases
Solution Approach 1:
The patent systematically optimizes formulation parameters including cyclodextrin agent concentration (0.1% to 60% w/w), disintegrant content (1% to 20% w/w), and particle size distribution to achieve immediate release characteristics. This structured parameter optimization enables rapid dissolution (85% in 15 minutes) while managing formulation complexity through methodical development approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective immediate release of the active ingredients, meeting in vitro dissolution criteria with high compactibility and reduced sticking during compaction, allowing for proportional formulations and protection against degradation.
Implementation Method 1
A pharmaceutical composition comprising particles, said particles comprising an active ingredient and 0.1% to 60% per weight of at least a cyclodextrin agent
Implementation Method 2
utilizing a dry granulation process that enhances compaction and dissolution profiles
Implementation Method 3
The oral composition of the invention is in a solid form... meeting in vitro dissolution criteria with high compactibility
Data Source
AI summary
The present invention relates to an immediate release formulation of pharmaceutical compounds.